TABLE 1-continued

4	12577-8	0,8 ml FYSKOSAL (0,15M NaCL)	4	75
5	13426-8	Fyskosal	4	80
5	13429-8	Fyskosal	2+	25
5	13435	Fyskosal	4	80
3a	13010-8	0,8 ml 1% Na-hyaluronat	2+	5
3a	13016-8	0,8 ml 1% Na-hyaluronat	3+	2
3a	13017-8	0,8 ml 1% Na-hyaluronat	1	0
3a	13021-8	0,8 ml 1% Na-hyaluronat	1	0
3b	12559-8	0,8 ml 1% Na-hyaluronat	1	0
3b	12563-8	0,8 ml 1% Na-hyaluronat	1	0
3b	12565-8	0,8 ml 1% Na-hyaluronat	1	0
3b	12570-8	0,8 ml 1% Na-hyaluronat	3	5
3b	12573-8	0,8 ml 1% Na-hyaluronat	1	0
3b	12583-8	0,8 ml 1% Na-hyaluronat	3	10
3a	13009-8	0,8 ml 1%HA10%DX70	1	0
3a	13018-8	0,8 ml 1%HA10%DX70	1	0
3a	13014-8	0,8 ml 1%HA10%DX70	1	0
3b	12561-8	0,8 ml 1%HA10%DX70	2+	2
3b	12566-8	0,8 ml 1%HA10%DX70	1	0
3b	12567-8	0,8 ml 1%HA10%DX70	1	0
3b	12568-8	0,8 ml 1%HA10%DX70	1	0
3b	12571-8	0,8 ml 1%HA10%DX70	1	0
3b	12582-8	0,8 ml 1%HA10%DX70	1	0
4	12585-8	0,8 ml 0,5%HA10%DX70 + 3%DX1	3	50
4	12579-8	0,8 ml 0,5%HA10%DX70 + 3%DX1	1	0
4	12575-8	0,8 ml 0,5%HA10%DX70 + 3%DX1	2	5
4	12572-8	0,8 ml 0,5%HA10%DX70 + 3%DX1	3	1
4	11876-8	0,8 ml 0,5%HA10%DX70 + 3%DX1	1	0
4	12588-8	0,8 ml 0,5%HA10%DX70 + 3%DX1	3	3
4	12586-8	0,8 ml 10%DX70	2	40
4	12560-8	0,8 ml 10%DX70	3	20
4	12576-8	0,8 ml 10%DX70	3	20
4	11872-8	0,8 ml 10%DX70	3	35
4	12578-8	0,8 ml 10%DX70	3	40
4	12581-8	0,8 ml 10%DX70	3	65
5	13437-8	0,8 ml 1%HA5%DX70	2	5
5	13438-8	0,8 ml 1%HA5%DX70	1	0
5	13432-8	0,8 ml 1%HA5%DX70	1	0
5	13440-8	0,8 ml 1%HA5%DX70	1	0
5	13443-8	0,8 ml 1%HA5%DX70	3	20
5	11871-8	0,8 ml 1%HA5%DX70	1	0
5	11877-8	1,6 ml 0,5%HA	2	1
5	13441-8	1,6 ml 0,5%HA	1	0

TABLE 1-continued

5	13433-8	1,6 ml 0,5%HA	3	35
5	13442-8	1,6 ml 0,5%HA	1	0
5	10953-8	1,6 ml 0,5%HA	2+	10

As is evident from the results above, the effect of dextran was not significantly different from that of the controls whereas hyaluronic acid alone had a distinct effect, although even in this group adhesions were recorded in 40% of the cases, albeit with limited surface attachment. However, in the group which received the composition according to the invention, it was possible to prevent adhesions in 90% of the cases and the only adhesion noted was very minor and located at the operation incision.

The compositions according to the invention have thus proved to have a surprising capability of preventing postoperative complications in the form of adhesions, and the result thus offers considerable promise for human trials.

REFERENCES

Weiss C et al (1986): The role of Na-hylan in reducing postsurgical tendon adhesions Bull Hosp Jt Dis Orthop Inst 46(1), 9–15

Robison Robert J et al (1984): Prevention of Pericardial Adhesions with Dextran 70 The Annals of Thoracic Surgery 37(6), 488–490

Von Messmer K et al (1980): Anaphylaktoide Reaktionen nach Dextran Allergologie, Jahrgang 3, Nr 2/1980, Sonderausgabe, 17–24.

I claim:

1. Method for preventing adhesion between tissue surfaces, which comprises implanting into the space in which adhesions are to be prevented a composition comprising an admixture of dextran in an amount 1 to 35% and hyaluronic acid in an amount of 0.5 to 6%, the dextran having a weight average molecular weight within the range of 30,000 to 75,000 and the hyaluronic acid having a weight average molecular weight within the range of 500,000 to 6,000,000.

2. A method according to claim 1 wherein said composition contains a hapten-dextran.

* * * * *